Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Ajovy

EU flag

Orphan drugs in latest CHMP recommendations

EMA advisers back new products from Genzyme, Boehringer and others

Teva Pharma logo

Cuts help Teva raise profits, despite flat sales

Earnings attributed largely to firm’s generics business

Teva Pharma logo

Teva scales back R&D as Copaxone competition looms

Copaxone accounts for almost 40% of its revenue

- PMLiVE

Questions raised about affordability of asthma antibodies

Positive data on GSK and Teva anti-IL-5 candidates at ERS congress highlights cost concerns

- PMLiVE

Teva supports launch of MS help website

Pow Health aims to help patients in Ireland with long term illnesses

- PMLiVE

Teva stakes its claim to the asthma antibody market

Plans to file reslizumab early next year

- PMLiVE

EU hits Servier and generic firms with €428m ‘pay-for-delay’ fine

Follows deals to delay competition for blood pressure drug Coversyl/Aceon

- PMLiVE

Teva’s chair Philip Frost to step down

He will leave the Israeli pharma company by the end of the year

- PMLiVE

Teva restructures to stengthen unit identities

First major change at Israeli firm since Erez Vigodman’s appointment as CEO

- PMLiVE

Teva to use cloud-based CRM for sales force

Picks Veeva’s system to streamline operations

- PMLiVE

Teva backs laquinimod for MS despite CHMP rejection

EMA confirms negative opinion after re-examination

- PMLiVE

Teva launches first generic of GSK’s Lovaza in US

Will have six months of marketing exclusivity for copy of cardiovascular drug

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links